Shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) have been given a consensus recommendation of “Buy” by the seven brokerages that are covering the firm, Marketbeat reports. One investment analyst has rated the stock with a hold recommendation, five have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $13.25.
A number of equities research analysts recently issued reports on the company. BidaskClub upgraded Aurinia Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday, October 5th. Cantor Fitzgerald set a $18.00 price objective on Aurinia Pharmaceuticals and gave the stock a “buy” rating in a research report on Monday, October 1st. HC Wainwright reiterated a “buy” rating and issued a $15.00 price objective on shares of Aurinia Pharmaceuticals in a research report on Wednesday, September 26th. Zacks Investment Research downgraded Aurinia Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, October 15th. Finally, ValuEngine upgraded Aurinia Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday, August 28th.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Ironwood Investment Management LLC grew its stake in shares of Aurinia Pharmaceuticals by 18.0% during the second quarter. Ironwood Investment Management LLC now owns 218,568 shares of the biotechnology company’s stock valued at $1,231,000 after buying an additional 33,279 shares during the last quarter. Stanley Laman Group Ltd. bought a new position in shares of Aurinia Pharmaceuticals during the second quarter valued at about $276,000. FMR LLC grew its stake in shares of Aurinia Pharmaceuticals by 2.1% during the third quarter. FMR LLC now owns 4,680,959 shares of the biotechnology company’s stock valued at $31,082,000 after buying an additional 95,650 shares during the last quarter. Franklin Resources Inc. grew its stake in shares of Aurinia Pharmaceuticals by 6.1% during the third quarter. Franklin Resources Inc. now owns 1,838,500 shares of the biotechnology company’s stock valued at $12,208,000 after buying an additional 105,300 shares during the last quarter. Finally, Jane Street Group LLC bought a new position in shares of Aurinia Pharmaceuticals during the third quarter valued at about $182,000. Institutional investors and hedge funds own 25.18% of the company’s stock.
Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last issued its quarterly earnings data on Thursday, November 8th. The biotechnology company reported ($0.21) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.17) by ($0.04). Aurinia Pharmaceuticals had a negative return on equity of 36.10% and a negative net margin of 7,280.85%. The business had revenue of $0.38 million during the quarter, compared to analysts’ expectations of $0.07 million. Sell-side analysts predict that Aurinia Pharmaceuticals will post -0.73 earnings per share for the current fiscal year.
Aurinia Pharmaceuticals Company Profile
Aurinia Pharmaceuticals Inc, a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutic drugs for the treatment of autoimmune diseases in Canada, the United States, China, and Switzerland. The company is developing voclosporin, a calcineurin inhibitor for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis.
Further Reading: What is a closed-end mutual fund (CEF)?
Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.